Mainz Biomed to Provide Interim Update on eAArly DETECT 2 Study by End of Summer 2025

Strategic Insights -

Mainz Biomed, a molecular genetics diagnostic company, has announced plans to provide an interim readout of its eAArly DETECT 2 study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test, which integrates proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test. The study aims to validate industry-leading results and support the transition of CRC screening to CRC prevention. Mainz Biomed expects to complete enrollment in the second half of 2025 and report top-line results by the fourth quarter of 2025. The study's outcome will inform the protocol for ReconAAsense, the Company's U.S. pivotal study, which is on track to initiate in 2026.

Key Takeaways:

  • Mainz Biomed intends to provide an interim readout of its eAArly DETECT 2 study by the end of summer 2025.
  • The study is evaluating the Company's next-generation CRC screening test that integrates proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test.
  • The test aims to detect cancerous polyps with a high degree of accuracy and potentially prevent the disease through early detection of precancerous adenomas.
  • The eAArly DETECT 2 study will evaluate five novel gene expression (mRNA) biomarkers acquired from Sherbrooke University in 2022.
  • The biomarkers have demonstrated a unique ability to identify advanced adenomas and early-stage CRC.
  • The study will further evaluate and confirm the effectiveness of these biomarkers combined with Mainz Biomed's proprietary algorithm.
  • The study is expected to complete enrollment in the second half of 2025, with top-line results to be reported by the end of 2025.
  • The outcome of the study will inform the protocol for ReconAAsense, the Company's U.S. pivotal study, which is on track to initiate in 2026.

Statistics:

  • The eAArly DETECT 2 study is evaluating a population of approximately 2,000 average-risk patients.
  • Mainz Biomed expects to complete enrollment in the study in the second half of 2025.
  • Top-line results are targeted for the fourth quarter of 2025.
  • The Company's proprietary algorithm is being developed in conjunction with the novel gene expression (mRNA) biomarkers acquired from Sherbrooke University in 2022.
  • The study aims to enhance diagnostic sensitivity and specificity for early-stage CRC, while also identifying advanced adenomas.

Sources:

  • Mainz Biomed N.V. (NASDAQ:MYNZ) press release, dated [no date provided]